Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained the drug registration certificate issued by China's National Medical Products Administration for its Empagliflozin tablets in 10 milligrams dosages, a Tuesday Hong Kong bourse filing said.
The drug is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor jointly developed by Boehringer Ingelheim and Eli Lilly. It is used for the treatment of type 2 diabetes in adult patients with symptomatic chronic heart failure.
It works by reducing glucose abortion by the kidneys and by promoting the direct excretion of glucose from the urine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.